1. Introduction {#sec0005}
===============

Stem cell-based therapies currently hold great promise to treat a large number of diseases including cardiovascular diseases \[[@bib0005]\]; neurodegenerative diseases \[[@bib0010]\]; muscular degenerative disorders \[[@bib0015]\]; haematopoietic and immune system disorders \[[@bib0020]\]; liver injuries \[[@bib0025]\]; metabolic disorders \[[@bib0030]\]; cancers \[[@bib0035]\] and much more diseases in the human body that might take advantage of stem cell therapy. Mesenchymal stem or stromal cells (MSCs) in particular are a heterogeneous population of non-hematopoietic stem cells \[[@bib0040]\]. According to the minimal criteria set by the International Society for Cellular Therapy (ISCT), MSCs are characterized by their adherence to plastic; in vitro differentiation into osteoblasts, adipocytes and chondroblasts; expression of cell surface markers of CD105, CD73, CD44 and CD90 and lack of expression of CD45, CD34, CD11b, CD14, CD79a and HLA-DR \[[@bib0045]\]. Their multipotential differentiation ability combined with their relative ease of isolation and expansion in vitro have captured the attention of scientists worldwide as an appealing candidate for a wide range of therapeutic applications \[[@bib0050]\]. Despite initially harvested from the bone marrow, MSCs can now be derived from multiple sources such as adipose tissue, placenta, umbilical cord, dental pulp, skin and others \[[@bib0055]\]. Given all of the above, the therapeutic use of MSCs for many diseases has been substantially explored which is obvious through the increasing numbers of preclinical and clinical trials of MSC-based products that has risen exponentially over the last 10 years.

During the past decade, research in the field of stem cells has expanded significantly and many trials have been carried out to exploit the ability of MSCs to treat diseases including musculoskeletal, cardiovascular, neurodegenerative and metabolic diseases \[[@bib0060]\]. However, comparatively, there is less work done in exploring their therapeutic potential in infectious diseases. Even less is known regarding the utility of MSC for the treatment of viral infections.

The emergence of new viruses such as the novel coronavirus disease (COVID-19) virus pose serious threats to public health \[[@bib0065]\]. Due to the current absence of drugs or vaccines to treat infected patients with COVID-19; scientist are interested in moving from conventional to safe and effective MSC-based therapies owing to their immunomodulatory and tissue-repair properties \[[@bib0070]\]. This review will address the development of MSC clinical trials over the last 10 years with in-depth exploration of MSC-based therapies in viral diseases such as HIV, hepatitis and COVID-19.

2. Therapeutic applications of MSCs in the last decade {#sec0010}
======================================================

Data were extracted from ClinicalTrials.gov (NIH, Bethesda, Maryland, USA) using the term "mesenchymal" for trials registered between 1st of January 2010 and 4th of March 2020 yielding 923 trials of MSC-based interventions for investigation of their therapeutic potential. The highest activity is found in east Asia (32.6 %) mainly China; followed by North America (19.2 % with 18.4 % in the United States) and Europe coming in third place with 18.1 % as shown in [Fig. 1](#fig0005){ref-type="fig"} C. Currently, China conducts almost 22.5 % of all MSC-based trials registered. That is not surprising as the Chinese government has invested a substantial amount of money which is around 3 billion yuan (460 million dollars) to support stem cell and translational research in its twelfth Five-year plan (2011--2015). Moreover, China's latest thirteen's Five-year plan for biotechnology that was released in 2016 sets stem cells as one of the key research tasks to be supported.Fig. 1Number of registered MSC-based clinical trials collected from clinicaltrial.gov from 2010 to March 2020 with the term \"mesenchymal\" listing 923 trials (A). Distribution of MSC-based clinical trials around the world (B). Number (C) and percentage (D) of MSC clinical trials by disease classification.Fig. 1

The total number of registered trials increased linearly from 2010 to 2012, and almost tripled during this period ([Fig. 1](#fig0005){ref-type="fig"}A). However, there was a dramatic drop in 2013 followed by slow increase to reach 110 trials in 2015 after which they appear to have plateaued between 2016 and 2018, then the number of new trials seems to pick up in 2019.

The clinical trials were then divided into 8 groups by disease classification and the remainder was designated as others. Based on disease categories, nervous system diseases is the largest group which accounts for 18.1 % of all trials. The second most common condition for MSC trials is musculoskeletal diseases (154 trials) accounting for 16.7 % of MSC trials including 88 for osteoarthritis. Combined with MSC trials for cardiovascular diseases (121 trials), these three categories make almost half of the ongoing clinical trials (48 %). On the other hand, MSC-based therapies for infectious diseases comprises only 2.7 % of all trials with only 13 trials studying MSCs and their therapeutic applications in viral diseases.

3. MSCs to prevent or treat viral diseases {#sec0015}
==========================================

3.1. MSCs and human immunodeficiency virus (HIV) {#sec0020}
------------------------------------------------

Since HIV was discovered in 1983, researchers worldwide are still haunting an effective treatment for HIV infections \[[@bib0075],[@bib0080]\]. HIV pathogenesis is characterized by selective and progressive loss of CD4 T cells, leading to immunodeficiency in HIV-infected patients \[[@bib0085]\]. Highly active anti-retroviral therapy, referred to as HAART, is very effective in suppressing plasma HIV viral load leading to significant immune restoration and subsequently reduction in morbidity and mortality in chronic HIV-infected patients \[[@bib0090],[@bib0095]\]. However, there is a group of patients known as nonimmune responders (NIRs) who fail to reverse the immunodeficiency despite the full viral suppression making them susceptible to opportunistic infections and thus lower life expectancies as compared to those of immune responders \[[@bib0100]\]. Therefore, treating HIV-infected HAART-treated NIRs patients has become a daunting challenge and alternative treatment options are required. In the last decade, stem cell-based therapy provided a glimmer of hope for patients living with HIV. In fact, it was the hematopoietic stem cells (HSCs) that took center stage after the so called 'Berlin patient' was functionally cured from HIV after HSC transplantation with donor cells not expressing the C---C chemokine receptor type 5 (CCR5) which is essential for the HIV entry process \[[@bib0105]\]. Nearly a decade after the first case of sustained HIV remission in the 'Berlin patient' was announced, Gupta and collaborators reported the second case named 'London patient' who similarly underwent HSC transplantation with cells lacking CCR5 \[[@bib0110]\]. However, using allogeneic HSCs in HIV-infected patients is not without its limitations. Strong immunogenicity and occurrence of graft-versus-host disease (GvHD) remain at the forefront of concern when using this allogenic HSC transplantation \[[@bib0115]\]. Unlike HSCs, hypoimmunogenicity and unique immunosuppressive properties of MSCs have made them attractive candidates for treatment of HIV-infected individuals \[[@bib0120]\].

An interesting pilot study was conducted by Zhang and colleagues in 2013 to assess the safety and efficacy of umbilical cord MSCs (UC-MSCs) in HIV-infected NIR patients \[[@bib0125]\]. UC-MSC therapy was clinically and biologically tolerated by all patients with no recognized adverse effects throughout the trial under the registration number NCT01213186 \[[@bib0130]\]. Moreover, UC-MSC transfusion induced a significant elevation in CD4 T-cell numbers and reduction in proinflammatory cytokines levels \[[@bib0125]\]. However, the mechanisms by which UC-MSC treatment reduced the overactivation of the immune system in NIRs are still far from clear. A phase I/II clinical trial (NCT02290041) is also evaluating the safety and efficiency of intravenous infusion of allogenic adipose-derived MSCs (AD-MSCs) in HIV-infected patients with discordant immunologic and virologic responses to HAART \[[@bib0135]\] (see [Table 1](#tbl0005){ref-type="table"} ).Table 1Ongoing clinical trials on the use of Mesenchymal stem cells in the treatment of virus infections.Table 1TitleVirusPatientsAimsPhaseStart dateTrial numberLocationRefs1Treatment with Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)Corona Virus Disease 2019 (COVID-19)90to assess treatment with three intravenous doses of MSCs 4.0\*10^7^ cells per time) compared with placebo, all of them receive the conventional treatmentI/II2020NCT04288102China472Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel CoronavirusCorona Virus Disease 2019 (COVID-19)20to inspect the safety and efficiency of Mesenchymal Stem Cells (MSCs) therapy for pneumonia patients infected with 2019-nCoV.I2020NCT04252118China463A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus PneumoniaCorona Virus Disease 2019 (COVID-19)30to explore the safety and efficiency of aerosol inhalation of the exosomes derived from allogenic adipose mesenchymal stem cells (MSCs-Exo) in the treatment of severe patients hospitalized with novel coronavirus pneumonia (NCP)I2020NCT04276987China484Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe PneumoniaCorona Virus Disease 2019 (COVID-19)48to inspect the safety and efficiency of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) therapy for severe pneumonia patients infected with 2019-nCoV.N.A.2020NCT04273646China445Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus (nCOV) PneumoniaCorona Virus Disease 2019 (COVID-19)10To assess safety and efficacy of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOVII2020NCT04269525China456Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant ResponseHuman Immunodeficiency Virus5to Assess the Safety and Efficiency of the Treatment With Allogenic Adult Mesenchymal Stem Cells From Adipose Tissue Expanded, in HIV-infected Patients With Controlled Viremia and Immunological Discordant ResponseI/II2017NCT02290041Spain277Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected PatientsHuman Immunodeficiency Virus72to learn what dose of transfused MSC reduces the level of activation of CD8 cells in people infected with HIV.II2013NCT01213186China268Clinical Study of Human Umbilical cord Mesenchymal Stem Cells(19\#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b CirrhosisHepatitis B Virus20to evaluate the effectiveness and safety of human umbilical Mesenchymal stem cells in patients with hepatitis B cirrhosisI2018NCT03826433China9Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver CirrhosisHepatitis B & C Viruses200to investigate the safety and efficacy of mesenchymal stem cells in hepatitis B and C related liver cirrhosis patientsN.A.2017NCT03209986China4010Mesenchymal Stem Cells Transplantation for Liver Cirrhosis Due to HCV HepatitisHepatitis C virus5To study the efficacy of Adipose Tissue Derived Autologous Repeated Mesenchymal Stem Cells Transplantation Via Hepatic Artery and Peripheral Vein in Patients With Liver Cirrhosis Due to HCV HepatitisI/II2016NCT02705742Turkey11Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Plasma Exchange for Patients With Liver FailureHepatitis B Virus120to investigate safety and efficacy of human umbilical cord mesenchymal stem cells (UC-MSCs) transplantation combined with plasma exchange (PE) for patients with liver failure caused by hepatitis B virusI/II2012NCT01724398China3812Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by Hepatitis B Virus (HBV)Hepatitis B Virus120II2011NCT01322906China3713MSC for Treatment of CMV Infectioncytomegalovirus (CMV)120to evaluate the efficacy of mesenchymal stem cells (MSC) in the treatment of refractory cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Phase2014China

Although HAART has been very successful in suppressing HIV replication and improving clinical outcomes, it cannot eliminate latent HIV reservoirs and thus fails to cure HIV infection \[[@bib0140]\]. Therefore, there is an increasing need to develop novel strategies to reactivate latent HIV reservoirs and subsequently enhance their clearance. An in vitro study using latent HIV-infected cell lines reported a novel role for MSCs and MSC-secretome in HIV-1 latency-reactivation through PI3K and NFκB signaling pathways \[[@bib0145]\]. However, further research is needed to understand the efficacy of MSCs in reactivation of HIV-1 within reservoir microenvironments in vivo.

3.2. MSCs and hepatitis B virus (HBV) {#sec0025}
-------------------------------------

Chronic infection with Hepatitis B virus (HBV) is a serious life-threatening condition affecting 260 million humans which is more than 3 % of the word population and causing more than 880,000 deaths annually due to liver failure or hepatocellular carcinoma \[[@bib0150]\]. HBV-related acute-on-chronic liver failure (HBV-ACLF) is observed in populations with chronic HBV infections and associated with high mortality rates due to limited treatment options \[[@bib0155]\]. Current therapies available are nucleos(t)ide analogues that help in reducing cirrhosis and liver-related mortality by suppressing HBV replication, but cannot eliminate the virus \[[@bib0160]\]. Interferon-α treatment can clear HBV in a low number of patients but its use is limited by severe side effects \[[@bib0165]\]. Besides, Artificial Liver Support System (ALSS) therapy has been developed and widely employed for the treatment of patients with HBV-ACLF; however, it is mainly used as a bridge to liver transplantation which is the only highly efficient therapy for HBV-ACLF patients poorly-responding to standard medical treatment \[[@bib0170]\]. Nevertheless, Liver transplantation is limited because of rapid disease progression and organ scarcity \[[@bib0170],[@bib0175]\].

In the era of regenerative medicine, MSCs have emerged as a novel approach for HBV-ACLF treatment due to their ability to home to damaged tissues, hypoimmunogenicity that allows allogenic transplantation, anti-inflammatory effects and their differentiation capacity into functional hepatocyte-like cells \[[@bib0180],[@bib0185]\]. An study by Peng and colleagues investigated the therapeutic effects of single transfusion of culture expanded autologous Bone marrow (BM)-MSCs in HBV-associated liver failure patients \[[@bib0190]\]. BM-MSC transplantation was proven safe for those patients with short term efficacy as measured by improvement of albumin, total bilirubin, prothrombin time and Model for End‐Stage Liver Disease (MELD) scores compared to the control group \[[@bib0190]\]. However, the MSC therapy could not markedly improve the clinical laboratory measurements in a long‐term follow-up, which could be explained by the slow proliferation of autologous MSCs derived from hepatitis B patients thus delaying timely intervention \[[@bib0190]\].

Regarding clinical application of MSCs in HBV-infected patients, there are actually four trials registered at clinicaltrials.gov in the last decade, as shown in [Table 1](#tbl0005){ref-type="table"}, with each one of them employing allogenic MSCs instead of autologous. Lin and colleagues reported the findings of a prospective, phase II, randomized controlled trial (NCT01322906) showing that allogeneic BM-MSC infusion was safe with no serious adverse effects in patients with HBV-ACLF \[[@bib0195]\]. Moreover, MSC infusions improved hepatic function as total bilirubin and MELD scores and decreased the incidence or severity of infections and death, which could be due to the immunomodulatory properties of MSCs \[[@bib0195]\]. In another recent clinical study (NCT01724398) conducted by Xu et al. to determine the safety and efficacy of UC-MSC transplantation combined with plasma exchange (PE) therapy for HBV-ACLF patients, results showed that the combined treatment was safe which was in agreement with a similar study by Li et al. \[[@bib0200],[@bib0205]\]. However; the short-term prognosis was not markedly improved as compared with single treatment \[[@bib0200]\]. Currently, two randomized controlled trials (NCT03209986; NCT03109236) are in the process of recruiting to determine the potential clinical benefits of MSC-based therapy for treatment of patients with hepatitis B related liver cirrhosis \[[@bib0210],[@bib0215]\].

Despite all the evidence of the MSCs therapeutic abilities in HBV infection suppression, these results are non-conclusive and thus further studies are required specifically to understand the outcomes of the long-term use of MSCs to treat HBV-ACLF and all the mechanisms involved in liver regeneration.

3.3. MSCs and COVID-19 {#sec0030}
----------------------

Coronaviruses are members of large viral family causing mild respiratory diseases to severe fatal infections such as Severe Acute Respiratory Syndrome (SARS) that emerged firstly in China in 2002/2003, Middle East Respiratory Syndrome (MERS) that emerged initially in Saudi Arabia in 2012, and recently the emergence of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and that has grown to be a global pandemic since patients were first detected in China, in December 2019 \[[@bib0065]\]. At present, there are no available anitviral drugs or vaccines to treat patients with COVID-19. The mainstay of medical management is currenlty symptomatic treatment, with care and support to the vital organ functions for seriously ill patients \[[@bib0220]\]. Therefore, there is a pressing need for an effective therapeutic approach for COVID-19 patients especially the critical cases.

A study by Huang et al. \[[@bib0220]\] have shown that COVID-19 infected patients had high circulating levels of proinflammatory cytokines with ICU-admitted patients showing elevated GCSF, IP10, MCP1, MIP1A, and TNFα levels when compatrd to non-admitted patients \[[@bib0220]\]. This indicates a cytokine storm in the lungs which is often associated with a flood of immune cell responses and subsequently pulmonary inflammation and extensive lung damage which might lead to death \[[@bib0220]\]. Hence, the key to COVID-19 treatment is to avoid the cytokine storm and thereby supress the super-inflammatory immunological response induced by SARS-CoV-2 thus reducing the lung injury, coupled with repair and regeneration of the lung tissue structure and function \[[@bib0225],[@bib0230]\].

Owing to their anti-inflammatory, immunomodulatory and homing properties as well as regenerative potential, MSCs have attracted the attention of many scientists as a cell-based therapy for the treatment for COVID-19. A recent pilot study by Leng et al. \[[@bib0230]\] issued in the Chinese Clinical Trial Registry (ChiCTR2000029990) has shown the effectiveness of MSCs in seven patients suffering from COVID-19 pneumonia in Beijing Hospital, China \[[@bib0230]\]. Two to four days after intravenous injection of MSCs; symptoms of fever, weakness and shortness of breath disappeared in the seven patients with significant improvement in the pulmonary function \[[@bib0230]\]. Leng and colleagues also reported a sharp decline in the major inflammatory marker C-reactive protein as well as pro-inflammatory cytokine TNF-α and a remarkable increase in the anti-inflammatory IL-10 in the MSC treated patinets \[[@bib0230]\]. Thus, the intravenous infusion of MSCs was found to be safe and successful in reversing the virus-induced cytokine storm and enhancing endogenous lung repair by improving the local pulmonary microenvironment \[[@bib0230]\]. Herein, this pilot study has yielded encouraging data paving the way for more trials on MSCs as a therapeutic approach to patients with COVID-19.

As of 5 March 2020, five clinical trials have shown up on Clinicaltrials.gov studying the safety and efficacy of MSCs in treatment of patients infected with COVID-19 as shown in [Table 1](#tbl0005){ref-type="table"}, all of which are being undertaken in China. Two ongoing trials are using Human UC-MSC therapy that were infused intravenously at a concentration of 0.5 × 10^6^ cells /kg body weight (NCT04273646) and 3.3 × 10^7^ cells /50 ml (NCT04269525), respectively \[[@bib0235],[@bib0240]\]. Another Phase I clinical trial (NCT04252118), where a total of three doses of MSCs (3.0 × 10^7^ cells) were administered, confirmed their safety in COVID-19 patients \[[@bib0245]\]. A parallel phase I/II study (NCT04288102) is also assessing the safety and efficiency of 3 doses of intravenously administered MSCs(4.0 × 10^7^ cells per dose) at days 0, 3 and 6 \[[@bib0250]\]. Moreover, a newly registered trial (NCT04276987) is intending to investigate the safety and efficacy of aerosol inhalation of allogenic AD-MSCs-derived exosomes in patients with COVID-19 Pneumonia \[[@bib0255]\]. The use of MSC-Exosomes as an alternative to parent MSCs will offer considerable advantages. One advantage is their ability to migrate efficiently to the target site because of their nanosized dimensions without getting physically trapped in microvasculature \[[@bib0260]\]. Moreover, with MSC exosomes, a higher 'dose' is quite guaranteed to the injured target tissue unlike their counterpart cells whose dose quickly decreases after infusion \[[@bib0265]\].

3.4. Conclusion & future perspectives {#sec0035}
-------------------------------------

Among all types of stem cells, MSCs remain the most commonly used in cell therapy as they are free from ethical concerns with low risk of teratoma formation. Moreover, their immunomodulatory, anti-inflammatory, regenerative capacity as well as homing abilities to damaged tissues have made MSCs a very popular candidate for preclinical and human clinical trials as shown in this review for patients with viral diseases. However, the limitations of these MSC-based therapies should never be underestimated. First, the heterogeneity of MSCs is a serious concern which might explain discrepancies in research results. Also, recent literature has shown increasing evidence that MSCs may not be immunologically silent as assumed previously. Therefore, there might be need for more research studies to determine ways to isolate the "immune privileged" subpopulations from the heterogeneous pool of MSCs for clinical applications. Another approach to avoid these limitations is the use of cell-free therapeutic strategies such as MSC-exosomes that will provide considerable benefits over their parent cells especially that the efficacy of MSC therapy appears to derive from the paracrine activity.

Due to the limited studies of MSCs on virus-associated diseases and because most of these investigations are still in the early clinical phases, their efficacy cannot be concluded at this time. Therefore, well-designed, randomized controlled trials with larger sample size are needed to validate MSC safety and therapeutic outcomes at both short and long-term follow up.
